Skip to main content
SpringerLink
Log in

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We have previously established a model for postmenopausal, hormone‐dependent breast cancer in nude mice which is responsive to both antiestrogens and aromatase inhibitors. In this model, MCF‐7 human breast carcinoma cells transfected with the aromatase gene (MCF‐7CA) synthesize sufficient estrogen to form tumors in ovariectomized nude mice. In the present study we used this intratumoral aromatase model to investigate the effects on tumor growth of the new nonsteroidal aromatase inhibitors letrozole (CGS 20,267) and anastrozole (ZD 1033) and the antiestrogens tamoxifen (ICI 47,474) and faslodex (ICI 182,780). Furthermore, we determined whether the inhibition of estrogen synthesis together with inhibition of estrogen action would be more effective in controlling breast tumor growth. The results of our studies indicate that the aromatase inhibitors anastrozole and letrozole, as well as the new pure antiestrogen faslodex, have potent antitumor effects in the mouse model. In the treatment of mice with mammary tumors, letrozole was more effective in suppressing tumor growth than anastrozole. This was consistent with the Ki values of these inhibitors against placental aromatase and the IC50 values in cell culture (MCF‐7CA), which indicated the greater potency of letrozole as an aromatase inhibitor. Letrozole also had greater antitumor effects than tamoxifen and faslodex. The antitumor effect of letrozole was substantial, making it difficult to detect any additional effect on the tumors when letrozole was combined with the antiestrogens. However, the combined treatment of anastrozole + tamoxifen and anastrozole + faslodex also did not increase efficacy compared to the aromatase inhibitor alone. In addition, combining the two antiestrogens did not suppress tumor growth more effectively than faslodex alone. Our results show that treatment with the combinations of aromatase inhibitors with either tamoxifen or faslodex are not more effective in blocking estrogen stimulation of tumor growth than the aromatase inhibitors alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hemsell DL, Grodin J, Brenner PF, Siiteri PK, MacDonald PC: Plasma precursors of estrogen II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 38: 476–479, 1974

    Google Scholar 

  2. McGuire WL: An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: Iacobelli, et al. (ed.) Hormones in Cancer, Vol. 15, Raven Press, NewYork, 1980, pp. 337–344

    Google Scholar 

  3. Cole MP, Jones CTA, Todd IDH: A new antiestrogen agent in the late breast cancer. An early clinical appraisal of ICI 46,474. Br J Cancer 25: 270–275, 1971

    Google Scholar 

  4. Early Breast Cancer Trials Collaborative Groups: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrence and 24,000 deaths among 75,000 women. Lancet 339: 1–15, 1992

    Google Scholar 

  5. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogen. Cancer Treat Rep 69: 237–238, 1985

    Google Scholar 

  6. Wakeling AE, Bowler J: Steroidal pure antiestrogen. J Endocr 112: R7–R10, 1987

    Google Scholar 

  7. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res. 51: 3867–3873, 1991

    Google Scholar 

  8. Schwarzel WC, Kruggel W, Brodie HJ: Studies on the mechanism of estrogen biosynthesis VII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 92: 866–880, 1973

    Google Scholar 

  9. Brodie AMH, Schwarzel WC, Shaikh AA, Brodie HJ: The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent process in production and breast cancer. Endocrinology 100: 1684–1695, 1977

    Google Scholar 

  10. Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie AMH: 4-Hydroxyandro-stenedione treatment of postmenopausal patients with advanced breast cancer. Lancet 2: 1237–1239, 1984

    Google Scholar 

  11. Goss PE, Coombes RL, Powles TJ, Dowsett M, Brodie AMH: Treatment of advanced postmenopausal breast cancer with aromatase inhibitor, 4-hydroxyandrostene-dione-Phase 2 report. Cancer Res 46: 4823–4826, 1986

    Google Scholar 

  12. Brodie AMH, Njar VCO: Aromatase inhibitors and breast cancer. Seminars in Oncology 23: 10–20, 1996

    Google Scholar 

  13. Bhatnagar AS, Batzl CH, Hausler A, et al: Endocrine and antitumor effects of nonsteroidal aromatase inhibitors. In: Motta M, Serio M (eds.) Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. New York, Elsevier, 1994, pp. 297–302, International Congress Series 1064

    Google Scholar 

  14. Plourde PV, Dyroff M, Dukes M: Arimidex: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat, 30: 103–111, 1994

    Google Scholar 

  15. Buzdar A, Jonat W, Howell A, Yin H, Lee D: Significant improved survival with arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials. Proceedings of ASCO., 16: 156a, 1997

    Google Scholar 

  16. Jonat W, Howell A, Blomqvist C et al: A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole ('Arimidex') with megasterol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A: 404–412, 1996

    Google Scholar 

  17. Trunet PF, Chaudri HA, Normberger U et al: Clinical use of letrozole in post-menopausal patients with advanced breast cancer (ABC). CIBA Symposium-‘Aromatase Inhibitors.’ Presented at German Cancer Congress, Berlin, Germany, February 22, 1996

  18. Marty M, Gershanovich M, Campos B, Romieu G, Lurie H, Bonaventura T, Jeffery M, Buzzi F, Ludwig H, Bodrigi I, Reichardt P, O'Higgins N, Chaudri HA, Friederich P, Biachoff MA: Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with antiestrogen. Proceedings of ASCO., 16: 156a, 1997

    Google Scholar 

  19. Yue W, Zhou DJ, Chen S, Brodie AMH: A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 54: 5092–5095, 1994

    Google Scholar 

  20. Yue W, Wang J, Savinov A, Brodie A: Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res 55: 3073–3077, 1995

    Google Scholar 

  21. Brodie A, Lu Q, Nakamura J. Aromatase in the normal breast and breast cancer. J Steroid Biochem Molec Biol 61: 281–286, 1997

    Google Scholar 

  22. Lu Q, Nakamura J, Savinov A, Yue W, Weisz J, Dabbs DJ, Wolz G, Brodie A: Expression of aromatase protein and mRNA in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancer. Endocrinology 137: 3061–3068, 1996

    Google Scholar 

  23. Miller WR, Forrest APM: Oestradiol synthesis by a human breast carcinoma. Lancet 2: 866–868, 1974

    Google Scholar 

  24. Lipton A, Santner SJ, Santen RJ, Harvey HA, Peil PD, White-Hershey D, Bartholomew MJ, Antle CE: Aromatase activity in primary and metastatic human breast cancer. Cancer 59: 779–782, 1987

    Google Scholar 

  25. Demers LM: Effects of fadrozole (CGS 16949A) and letrozole (CGS 20,267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 30: 95–102, 1994

    Google Scholar 

  26. Yue W, Wang J, Hamilton CJ, Demers LM, Santen RJ: In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58: 927–932, 1998

    Google Scholar 

  27. Lu Q, Wang J, Lui Y, Long B, Brodie A: The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 50: 63–71, 1998

    Google Scholar 

  28. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, Mc-Cue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87: 746–750, 1995

    Google Scholar 

  29. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker, MG: Inhibition of estrogen receptor-DNA binding by the pure antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87: 6833, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Experimental Therapeutics, University of Maryland, School of Medicine, Baltimore, MD, USA

    Qing Lu, Yang Liu, Brian J. Long, Dmitry Grigoryev, Mark Gimbel & Angela Brodie

Authors
  1. Qing Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brian J. Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dmitry Grigoryev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark Gimbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Angela Brodie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lu, Q., Liu, Y., Long, B.J. et al. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 57, 183–192 (1999). https://doi.org/10.1023/A:1006225601046

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006225601046

Search

Navigation